ZUG, Switzerland, Dec. 3, 2015 /PRNewswire/ -- In a recent survey of US-based rheumatologists (n=97), Spherix Global Insights observed a high rate of brand switching between biologic brands among patients with RA and PsA. According to Robbie McCarthy, Vice President of Rare Insights and Patient Portfolio at Spherix, "With an increasing number of biologic and novel treatment options such as Celgene's Otezla and Pfizer's Xeljanz now available, the competition for second and third line positioning is fierce. And, while most switching is initiated based on suboptimal efficacy, the patient voice in brand selection also plays an important role."
The research also highlights the divide between rheumatologists with regard to acceptance of an "Otezla before biologic" approach in PsA. Rheumatologists comfortable using Otezla as a first line therapy report significantly higher Otezla share than those who do not agree with this approach. Although payers may present some barriers to early use of Otezla, it is clear that securing the first line position, before biologics, will be key to continued growth of the brand.
Based on these findings, Spherix Global Insights recently conducted a robust patient audit of more than 3,000 biologic-treated patients with RA, PsA, Crohn's Disease and Ulcerative Colitis who were switched to a different biologic brand, Xeljanz (in RA) or Otezla (in PsA). RealWorld Dynamix™: Biologic Switching in RA, PsA and IBD provides deep insight into drivers behind the switching behavior, uncovering where brands are at risk and where brands have opportunities to make conversions. The final read out from this fieldwork will be available at the end of December.
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Zug, Switzerland with US offices in Cambridge, MA. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document are trademarks of their respective holders.
For more information
SOURCE Spherix Global Insights